RVL Pharmaceuticals PLC reports results for the quarter ended in December - Earnings Summary

RVL Pharmaceuticals

20/03/2023 13:31

* RVL Pharmaceuticals PLC  RVLP.OQ  reported a quarterly
adjusted
loss of 18 cents​​ per share for the quarter ended in December.
The mean expectation of six analysts for the quarter was for a
loss of 16 cents per share.
    * Revenue rose 242.9% to $9.81 million from a year ago;
analysts
expected $12.60 million. 
    * RVL Pharmaceuticals PLC's reported EPS for the quarter was
a
loss of 18 cents​.
    * The mean earnings estimate of analysts had risen by
about 0.7%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * RVL Pharmaceuticals PLC shares had risen by 17.9% this
quarter.
    * The company reported a quarterly loss of $18.32 million.
    * Wall Street's median 12-month price target for RVL
Pharmaceuticals PLC is $3.30 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 20 at 01:30 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.16          -0.18          Missed
 Sep. 30 2022      -0.16          -0.16          Met
 Jun. 30 2022      -0.21          -0.14          Beat
 Mar. 31 2022      -0.17          -0.25          Missed